8-K: AVITA Medical Names Interim CEO, Reports Q3 Revenue

AVITA Medical announced the departure of CEO James Corbett, appointing Chairman Cary Vance as Interim CEO, and reported preliminary third-quarter revenue of approximately $17 million.

Summary

• James Corbett departed from his roles as Chief Executive Officer and member of the Board of Directors of AVITA Medical, Inc., effective October 16, 2025.
• Cary Vance, the company's Chairman of the Board, has been appointed Interim Chief Executive Officer, effective immediately, and will continue to serve as Chairman.
• Board member Jan Reed has been appointed Lead Independent Director of the Board.
• Preliminary revenue for the third quarter ended September 30, 2025, is expected to be approximately $17 million.
• The company secured a waiver for the third quarter 2025 trailing 12-month net revenue covenant in connection with its credit agreement with OrbiMed.
• Discussions are ongoing with OrbiMed to redefine future covenants, with the outcome yet to be determined.
• The Board intends to engage an executive search firm to assist with selecting a permanent CEO, considering both internal and external candidates, including Mr. Vance.
• As Interim CEO, Mr. Vance will receive an annualized base salary of $702,000 and is eligible for a guaranteed bonus payment for fiscal 2025 of $140,000.

Sentiment

Score: 4

Explanation: The departure of the CEO and the need for a revenue covenant waiver are significant negative indicators. While an experienced interim CEO has been appointed, the financial performance concerns and ongoing discussions with lenders create uncertainty. The preliminary revenue figure itself, without context of previous guidance, is hard to judge in isolation, but the waiver implies underperformance.

Positives

• The appointment of Cary Vance, an accomplished healthcare industry executive with over 30 years of leadership experience, as Interim CEO provides experienced leadership during the transition.
• Mr. Vance has a deep understanding of AVITA Medical's strategy and operations from his prior service on the Board and as Chairman.
• James Corbett's departure was not the result of any disagreement with the company on matters relating to its operations, policies, or practices, suggesting an amicable separation.
• The company successfully secured a waiver for the third quarter 2025 trailing 12-month net revenue covenant with OrbiMed, avoiding a potential breach.

Negatives

• The preliminary third-quarter revenue of approximately $17 million, coupled with the need for a covenant waiver, suggests potential underperformance or slower-than-expected growth.
• The ongoing discussions with OrbiMed to redefine future covenants indicate that the company's financial trajectory may not align with previous expectations or agreements, creating uncertainty.
• The departure of a CEO can introduce instability and uncertainty regarding the company's strategic direction and future performance.

Risks

• Failure to obtain and/or maintain regulatory approvals and comply with applicable regulations.
• Market reaction to growth or product initiatives.
• Market penetration of the company's products.
• Changes in the legal or regulatory environments.
• Other business effects, including the effects of industry, as well as other economic or political conditions outside of the company's control.
• Uncertainty regarding the outcome of discussions with OrbiMed to redefine future covenants, which could impact financing terms.
• Potential for disruption during the executive search for a permanent CEO.

Future Outlook

The company is assessing annual guidance and will provide an update on its third-quarter earnings call scheduled for November 6, 2025. The Board intends to engage an executive search firm to assist with selecting a permanent CEO, considering both internal and external candidates, including Mr. Vance. Discussions are ongoing with OrbiMed to redefine future covenants, with the outcome yet to be determined.

Management Comments

• We are pleased that Cary is taking on this role at an important time for the Company. He not only brings a proven track record of leading operational improvement initiatives and commercialization processes, but he also has a deep understanding of AVITA Medicals strategy and operations from his time on the Board.
• It is a privilege to lead AVITA Medical as we continue advancing innovative solutions across our integrated, multi-product wound care platform. With our strong foundation built on delivering transformative solutions to patients, we remain laser-focused on executing across our business to unlock our portfolios full potential and return to growth so we can deliver long-term value for our shareholders. I am excited to work closely with the executive leadership team and our dedicated employees to continue optimizing wound healing and accelerating the time to patient recovery.

Industry Context

AVITA Medical operates in the therapeutic acute wound care sector, a specialized area within the broader healthcare and medical technology industry. The appointment of an interim CEO with extensive experience in medical technology and robotic-assisted surgery suggests a focus on commercialization and operational improvement, which are common themes in the competitive med-tech landscape. The preliminary revenue and covenant waiver indicate potential challenges in meeting financial targets, a situation that can affect companies across various healthcare sub-sectors facing market pressures or product adoption hurdles.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards.
• The preliminary Q3 2025 revenue of $17 million, coupled with the need for a covenant waiver from OrbiMed, suggests that the company's performance may be below internal or market expectations for its growth stage in the wound care industry.
• The appointment of an interim CEO and the initiation of a search for a permanent CEO is a standard corporate governance practice during leadership transitions, aligning with industry norms for ensuring continuity and seeking optimal long-term leadership.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential uncertainty due to CEO transition and financial performance concerns (covenant waiver), but also potential for improved strategic direction under new leadership.
• Employees: Leadership change may create uncertainty but also opportunities under new management.
• Creditors (OrbiMed): Ongoing discussions to redefine covenants indicate a need for revised financial agreements, potentially impacting terms or future lending.
• Customers: No direct impact mentioned, but stable leadership and financial health are crucial for long-term product development and support.

Next Steps

• Enter into a separation agreement with former CEO James Corbett consistent with his employment agreement.
• Engage an executive search firm to assist with selecting a permanent CEO, considering internal and external candidates.
• Continue discussions with OrbiMed to redefine future covenants.
• Provide an update on annual guidance during the third-quarter earnings call scheduled for November 6, 2025.

Key Dates

Recommendation

The filing presents a mixed bag of news. The departure of the CEO and the need for a revenue covenant waiver are concerning, suggesting potential underperformance or financial strain. This typically warrants a cautious approach. However, the appointment of an experienced interim CEO and the proactive engagement with lenders (OrbiMed) to redefine covenants show management is addressing challenges. The company's core business in wound care with the RECELL System remains a valuable asset. A "hold" recommendation is appropriate given the current uncertainties surrounding leadership and financial targets, awaiting further clarity from the Q3 earnings call and the outcome of covenant discussions before making a more definitive investment decision.

Keywords

AVITA Medical, RCEL, CEO Transition, Interim CEO, Cary Vance, James Corbett, Q3 Revenue, SEC Filing, 8-K, Wound Care, Medical Technology, Corporate Governance, OrbiMed, Revenue Covenant